Cell genomics
made easy
Services
We care for your cells
Stem Genomics provides specific services to assess the genetic integrity of stem cells. We offer a range of innovative tests that use digital PCR and a panel of specific probes to detect most of the recurrent genetic abnormalities observed in stem cells. This innovation, called iCS-digital TM, is rapid, robust, and cost-effective, and can be performed on genomic DNA, cell pellets and cells in fresh culture media (or in cell culture supernatant).
The iCS-digital TM PSC test detects more than 90% of recurrent genomic abnormalities in human pluripotent stem cells (hPSCs).
The iCS-digital TM MSC test detects more than 80% of the most frequent genomic abnormalities in human mesenchymal stromal/stem cells (hMSCs).
About
Stem Genomics
Stem Genomics develops a technology invented by Prof John De Vos and Dr Said Assou, researchers at the Institute for Regenerative Medicine & Biotherapy (IRMB), University of Montpellier, and co-founders of the company. Located at the heart of the University Hospital Centre of Montpellier, IRMB houses research groups working on basic stem cell research and on innovative applications for regenerative therapy, with the aim of facilitating the transfer from research to clinical applications. Stem Genomics is located at the IRMB Cyborg business incubator and works in close collaboration with IRMB researchers. Stem Genomics has emerged from a prestigious scientific environment.
References
They trust us
https://www.roche.com/
https://www.ncardia.com/
https://www.istem.eu/
https://bioneer.dk/
https://www.institut-vision.org/en/
https://golivertx.com/
https://institutducerveau-icm.org/
https://www.marseille-medical-genetics.org/
http://www.inmfrance.com/inmfrance-j3/index.php/en/
https://www.glycostem.com/home-page
https://www.takarabio.com/
https://www.institutimagine.org/en
http://parcc.inserm.fr/
https://www.dinaqor.com/
NCARDIA
The results are obtained very quickly; the reports are clearly interpreted and there is a smooth line of communication between Ncardia and Stem Genomics whenever we require further clarifications.
ICM
We have been using the (iCS-Digital™) tests since their launch in 2018 and find them to be very reliable.
GoLiver Therapeutics
“Since we started using the iCS-digital™ PSC for routine control, we have gained a massive degree of confidence in the quality of our cells in long-term culture […] Not surprisingly, by removing the genetic instability factor from the equation, we are rewarded with a highly scalable, efficient and very cost-effective GMP differentiation process for PSCs to produce safe live cell therapy products on a multi-billion cell scale."
Stay informed
Subscribe to our newsletter